C026 | IMMUNOMODULATORY EFFECT OF DASATINIB PLUS BLINATUMOMAB VERSUS PONATINIB PLUS BLINATUMOMAB IN NEWLY DIAGNOSED PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) PATIENTS

Introduction. In newly diagnosed Ph+ ALL, TKIs combined with immunotherapy are being increasingly explored. The GIMEMA D-ALBA trial used dasatinib in induction followed by blinatumomab as consolidation (dasa+blina), reporting long-term OS of 80% and 100% DFS in patients achieving complete molecular...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	M. Ansuinelli, M.S. De Propris, N. Peragine, M.C. Puzzolo, M. Di Trani, C. Skert, R. Cairoli, S. Sica, A. Rambaldi, A. Tucci, M. Cerrano, D. Vallisa, V. Cardinali, S. Chiaretti, A. Guarini, R. Foà
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Ferrata Storti Foundation 2025-09-01
Saila:	Haematologica
Sarrera elektronikoa:	https://haematologica.org/article/view/12890
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!